Blood

Vol. 148, Issue 1 Issue 1 2026
20
Articles

Articles in this Issue

Ferric carboxymaltose increases fracture risk in patients and reduces bone formation in mice with iron deficiency anemia

Sonja A. Wagner, Marlene Panzer, Elke Pertler et al. Jul 02, 2026 pp. 15-30 10.1182/blood.2025031806

Abstract Modern IV iron formulations allow treatment of iron deficiency anemia (IDA) with 1 or 2 infusions. Ferric carboxymaltose (FCM) is a widely used IV iron, which causes hypop...

Is low a go for pediatric AML?

Rishi S. Kotecha Jul 02, 2026 pp. 6-7 10.1182/blood.2026033776

EBV and immunodeficiency: the odd couple drawn to the brain

Andrés J. M. Ferreri Jul 02, 2026 pp. 4-6 10.1182/blood.2026033838

CD28+ CD8+ Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD

Zengkai Pan, Yujun Deng, Jingtao Huang et al. Jul 02, 2026 pp. 130-144 10.1182/blood.2025032587

Abstract Steroid-refractory (SR) disease develops in a substantial fraction of patients with grade II to IV acute graft-versus-host disease (aGVHD) and is associated with poor long...

ELISA-negative HIT: antibody recognition and relevance

Andreas Greinacher, Thomas Thiele Jul 02, 2026 pp. 10-11 10.1182/blood.2026034332

Bachmann PS, Piazza RG, Janes ME, et al. Epigenetic silencing of <i>BIM</i> in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. <i>Blood</i> . 2010;116(16):3013-3022.

Jul 02, 2026 pp. 146-146 10.1182/blood.2026034574

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant

Clive S. Zent, Enrico Tiacci, Robert J. Kreitman et al. Jul 02, 2026 pp. 31-42 10.1182/blood.2025032757

Abstract Hairy cell leukemia (HCL) and HCL variant (HCLv) are distinct, rare, and chronic splenic B-cell lymphomas/leukemias that partially overlap in clinicopathologic presentatio...

Chari A, van de Donk NWCJ, Dholaria B, et al. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. <i>Blood</i> . 2025;146(24):2902-2913.

Jul 02, 2026 pp. 147-148 10.1182/blood.2026034830

A step toward streamlining HIT diagnosis

Fernanda A. Orsi Jul 02, 2026 pp. 8-10 10.1182/blood.2026034052

A bone to pick with ferric carboxymaltose

Karin E. Finberg, Michael Auerbach Jul 02, 2026 pp. 1-2 10.1182/blood.2026033929

Low- vs standard-dose regimens as induction for pediatric AML: a multicenter, randomized noninferiority trial

Li Gao, Xiaowen Zhai, Ningling Wang et al. Jul 02, 2026 pp. 71-83 10.1182/blood.2025030972

Abstract Intensive chemotherapy is standard for acute myeloid leukemia (AML) but carries high risks of life-threatening complications, particularly in vulnerable patients. We aimed...

Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia

Lu Zhou, Andrew Cao, Wen Zhu et al. Jul 02, 2026 pp. 115-129 10.1182/blood.2025032317

Abstract The hallmark of heparin-induced thrombocytopenia (HIT) is the presence of immunoglobulin G (IgG) antibodies against platelet factor 4/heparin (PF4/H) complexes, typically...

Identifying steroid-refractory aGVHD before it happens

Daniel Teschner Jul 02, 2026 pp. 12-13 10.1182/blood.2026034423

Engineering single-chain variable fragments to identify pathogenic antibodies in heparin-induced thrombocytopenia

Anna-Lise Bissola, Donald M. Arnold, Yi Zhang et al. Jul 02, 2026 pp. 103-114 10.1182/blood.2025031696

Abstract Heparin-induced thrombocytopenia (HIT) is characterized by the production of pathogenic antibodies that bind to complexes of platelet factor 4 (PF4) and heparin, causing p...

Genomics reboot for secondary myelofibrosis

Natasha Szuber, Mrinal M. Patnaik Jul 02, 2026 pp. 3-4 10.1182/blood.2026033580

Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis

Barbara Mora, Francesca Palandri, Paola Guglielmelli et al. Jul 02, 2026 pp. 43-57 10.1182/blood.2025031366

Abstract Secondary myelofibrosis (SMF) represents a late stage of polycythemia vera (PV) and essential thrombocythemia (ET), with overall survival (OS) currently defined by the mye...

Therapy-related AML with MECOM rearrangement, biallelic TP53 inactivation, and striking nuclear abnormalities

Zhaodong XU, Tyler Smith Jul 02, 2026 pp. 145-145 10.1182/blood.2026033695

When the KAT’s away, vulnerability for AML comes out to play

William P. Tansey Jul 02, 2026 pp. 7-8 10.1182/blood.2026033894

Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML

Markus Meyerhöfer, Yawen Zhou, Aaron Gallego-Crespo et al. Jul 02, 2026 pp. 84-102 10.1182/blood.2025031924

Abstract The lysine acetyltransferase (KAT) activity of EP300 lysine acetyltransferase (p300)/CREB-binding protein (CREBBP) has traditionally been linked to transcriptional activat...

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study

Leon D. Kaulen, Lakshmi Nayak, Philipp Karschnia et al. Jul 02, 2026 pp. 58-70 10.1182/blood.2025031869

Abstract Immunodeficiency-associated primary central nervous system lymphoma (ID-PCNSL) represents a clinicopathologically distinct PCNSL subtype, for which large studies and progn...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page